|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/01/21 Wize Pharma, Inc. 10-K 12/31/20 85:6M EdgarAgents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 863K
2: EX-4.2 Description of Securities HTML 33K
3: EX-10.40 Amendment to Exclusive Distribution and Licensing HTML 33K
Agreement by and Between Wize Pharma Ltd., Ocuwize
Ltd. and Resdevco Research and Development Company
Ltd., Dated May 4, 2020
4: EX-21.1 Subsidiaries of the Company HTML 21K
5: EX-23.1 Consent of Independent Registered Public HTML 21K
Accounting Firm
6: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 23K
16: R1 Document and Entity Information HTML 60K
17: R2 Consolidated Balance Sheets HTML 105K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 39K
19: R4 Consolidated Statements of Comprehensive Loss HTML 62K
20: R5 Consolidated Statements of Changes in HTML 77K
Stockholders' Equity (Deficit)
21: R6 Consolidated Statements of Cash Flows HTML 147K
22: R7 General HTML 40K
23: R8 Significant Accounting Policies HTML 114K
24: R9 Marketable Equity Securities HTML 27K
25: R10 Other Current Assets HTML 27K
26: R11 License Agreement HTML 29K
27: R12 License Purchase Obligation HTML 31K
28: R13 Accounts Payable HTML 27K
29: R14 Convertible Loans HTML 60K
30: R15 Short Term Loan Payable HTML 24K
31: R16 Significant Transactions HTML 50K
32: R17 Taxes on Income HTML 48K
33: R18 Commitments and Contingencies HTML 28K
34: R19 Stockholders' Equity HTML 79K
35: R20 Selected Statements of Operations Data HTML 41K
36: R21 Related Parties Balances and Transactions HTML 32K
37: R22 Subsequent Events HTML 35K
38: R23 Significant Accounting Policies (Policies) HTML 169K
39: R24 Significant Accounting Policies (Tables) HTML 46K
40: R25 Other Current Assets (Tables) HTML 27K
41: R26 License Purchase Obligation (Tables) HTML 28K
42: R27 Accounts Payable (Tables) HTML 26K
43: R28 Convertible Loans (Tables) HTML 35K
44: R29 Significant Transactions (Tables) HTML 26K
45: R30 Taxes on Income (Tables) HTML 41K
46: R31 Stockholders' Equity (Tables) HTML 46K
47: R32 Selected Statements of Operations Data (Tables) HTML 41K
48: R33 Related Parties Balances and Transactions (Tables) HTML 32K
49: R34 General (Details) HTML 37K
50: R35 Significant Accounting Policies (Details) HTML 24K
51: R36 Significant Accounting Policies (Details 1) HTML 28K
52: R37 Significant Accounting Policies (Details 2) HTML 25K
53: R38 Significant Accounting Policies (Details 3) HTML 45K
54: R39 Significant Accounting Policies (Details 4) HTML 25K
55: R40 Significant Accounting Policies (Details 5) HTML 26K
56: R41 Significant Accounting Policies (Details Textual) HTML 67K
57: R42 Marketable Equity Securities (Details) HTML 39K
58: R43 Other Current Assets (Details) HTML 29K
59: R44 License Agreement (Details) HTML 37K
60: R45 License Purchase Obligation (Details) HTML 32K
61: R46 License Purchase Obligation (Details Textual) HTML 28K
62: R47 Accounts Payable (Details) HTML 32K
63: R48 Convertible Loans (Details) HTML 35K
64: R49 Convertible Loans (Details 1) HTML 42K
65: R50 Convertible Loans (Details Textual) HTML 159K
66: R51 Short Term Loan Payable (Details) HTML 31K
67: R52 Significant Transactions (Details) HTML 32K
68: R53 Significant Transactions (Details Textual) HTML 107K
69: R54 Taxes on Income (Details) HTML 31K
70: R55 Taxes on Income (Details 1) HTML 32K
71: R56 Taxes on Income (Details 2) HTML 35K
72: R57 Taxes on Income (Details Textual) HTML 52K
73: R58 Commitments and Contingencies (Details) HTML 28K
74: R59 Stockholders' Equity (Details) HTML 50K
75: R60 Stockholders' Equity (Details 1) HTML 55K
76: R61 Stockholders' Equity (Details Textual) HTML 174K
77: R62 Selected Statements of Operations Data (Details) HTML 42K
78: R63 Selected Statements of Operations Data (Details 1) HTML 58K
79: R64 Related Parties Balances and Transactions HTML 28K
(Details)
80: R65 Related Parties Balances and Transactions (Details HTML 25K
1)
81: R66 Related Parties Balances and Transactions (Details HTML 23K
Textual)
82: R67 Subsequent Events (Details) HTML 67K
84: XML IDEA XML File -- Filing Summary XML 148K
83: EXCEL IDEA Workbook of Financial Reports XLSX 131K
10: EX-101.INS XBRL Instance -- wizp-20201231 XML 1.45M
12: EX-101.CAL XBRL Calculations -- wizp-20201231_cal XML 152K
13: EX-101.DEF XBRL Definitions -- wizp-20201231_def XML 571K
14: EX-101.LAB XBRL Labels -- wizp-20201231_lab XML 1.18M
15: EX-101.PRE XBRL Presentations -- wizp-20201231_pre XML 883K
11: EX-101.SCH XBRL Schema -- wizp-20201231 XSD 268K
85: ZIP XBRL Zipped Folder -- 0001213900-21-012577-xbrl Zip 185K
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of Wize Pharma, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned principal executive officer of the Company, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (“SOX”), that:
| (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”); and |
| (2) | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of SOX and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Exchange Act. Such certification will not be deemed to be incorporated by reference into any filling under the Securities Act of 1993, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
A signed original of this written statement required by Rule 13a-14(b) or 15d-14(b) of the Exchange Act and Section 906 of SOX has been provided by the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
Date: March 1, 2021
| /s/ Noam Danenberg | |
|
Noam Danenberg,
|
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/1/21 | |||
| For Period end: | 12/31/20 | 4, 8-K | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/10/21 Mawson Infrastructure Group Inc. 424B3 1:412K EdgarAgents LLC/FA 10/29/21 Mawson Infrastructure Group Inc. S-3 4:515K EdgarAgents LLC/FA 9/30/21 Mawson Infrastructure Group Inc. 424B5 1:501K EdgarAgents LLC/FA 9/23/21 Mawson Infrastructure Group Inc. 424B5 1:495K EdgarAgents LLC/FA 8/17/21 Mawson Infrastructure Group Inc. S-8 8/17/21 4:256K EdgarAgents LLC/FA 8/05/21 Mawson Infrastructure Group Inc. S-3/A 2:677K EdgarAgents LLC/FA 7/30/21 Mawson Infrastructure Group Inc. S-3 3:359K EdgarAgents LLC/FA |